Holen Sie sich die Stockscreener-App
7.805
1.15%
0.085
Schlusskurs vom Vortag:
$7.72
Offen:
$7.78
24-Stunden-Volumen:
507.43K
Relative Volume:
0.45
Marktkapitalisierung:
$483.32M
Einnahmen:
$170.16M
Nettoeinkommen (Verlust:
$-312.76M
KGV:
-1.3732
EPS:
-5.6837
Netto-Cashflow:
$-178.72M
1W Leistung:
+13.50%
1M Leistung:
+14.84%
6M Leistung:
-50.67%
1J Leistung:
-5.35%
1-Tages-Spanne:
$7.66
$8.0172
1-Wochen-Bereich:
$6.165
$8.0172
52-Wochen-Spanne:
$5.37
$17.58
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Firmenname
Ginkgo Bioworks Holdings Inc
Sektor
Branche
Telefon
(877) 442-5362
Adresse
27 DRYDOCK AVENUE, BOSTON
Compare DNA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
7.805 | 478.06M | 170.16M | -312.76M | -178.72M | -5.6837 |
VRTX
Vertex Pharmaceuticals Inc
|
442.41 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.47 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
842.97 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
334.65 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
317.28 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-15 | Herabstufung | BTIG Research | Neutral → Sell |
| 2024-05-10 | Herabstufung | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-06-02 | Herabstufung | Goldman | Neutral → Sell |
| 2023-05-11 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Eingeleitet | Berenberg | Buy |
| 2022-10-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2022-02-23 | Eingeleitet | Goldman | Neutral |
| 2022-02-01 | Eingeleitet | BofA Securities | Neutral |
| 2022-01-28 | Eingeleitet | BofA Securities | Buy |
| 2022-01-07 | Eingeleitet | BTIG Research | Buy |
| 2021-11-29 | Eingeleitet | Jefferies | Buy |
| 2021-10-13 | Eingeleitet | Raymond James | Outperform |
| 2021-10-12 | Eingeleitet | William Blair | Outperform |
| 2021-09-20 | Eingeleitet | HSBC Securities | Buy |
Alle ansehen
Ginkgo Bioworks Holdings Inc Aktie (DNA) Neueste Nachrichten
DNA (NYSE: DNA) Rule 144 shows insider resale notices totaling tens of thousands of shares - Stock Titan
Ginkgo Bioworks CFO Coen sells $212k in shares By Investing.com - Investing.com India
Ginkgo Bioworks CFO Coen sells $212k in shares - Investing.com
Ginkgo Bioworks (NYSE: DNA) CFO nets PSU shares, sells stock for taxes - Stock Titan
Ginkgo Bioworks (DNA) major shareholder sells $802k in stock By Investing.com - Investing.com India
PSU vesting drives tax share sale for Ginkgo Bioworks (DNA) holder - Stock Titan
Reshma Shetty of Ginkgo Bioworks (DNA) sells shares to cover tax after PSU vesting - Stock Titan
DNA (NYSE: DNA) files Form 144: 33,171 Class A shares tied to vesting - Stock Titan
Proposed Class A sale by DNA (NYSE: DNA) — Form 144 lists 40,893 shares - Stock Titan
Ginkgo Bioworks Announces Date of Second Quarter 2024 Results Pr - GuruFocus
Aug Reactions: Is Ginkgo Bioworks Holdings Inc a strong candidate for buy and hold2026 Update & Stepwise Trade Signal Guides - baoquankhu1.vn
Trading Action: Is Ginkgo Bioworks Holdings Inc part of any major index2026 Closing Moves & Advanced Technical Signal Analysis - baoquankhu1.vn
DNA SEC FilingsGinkgo Bioworks Holdings Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Chart Watch: Can Ginkgo Bioworks Holdings Inc navigate macro headwindsPortfolio Performance Summary & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Ginkgo Bioworks CEO sells $1.37 million in shares By Investing.com - Investing.com South Africa
Ginkgo Bioworks CEO sells $1.37 million in shares - Investing.com
Ginkgo Bioworks 10% owner Canton sells $175k in DNA stock - Investing.com
Ginkgo Bioworks director Shetty sells $175k in shares - Investing.com
Ginkgo Bioworks director Shetty sells $175k in shares By Investing.com - Investing.com India
Tax-driven share sales follow PSU vesting at Ginkgo Bioworks (DNA) - Stock Titan
Tax-driven stock sales by major Ginkgo Bioworks (DNA) holder Barry Canton - Stock Titan
Ginkgo Bioworks (NYSE: DNA) insider vests PSUs, sells shares for taxes - Stock Titan
Director sales at DNA (NYSE: DNA) — 13,155 and 13,116 Class A shares - Stock Titan
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2025 earnings call transcript - MSN
DNA (NYSE: DNA) Form 144: 13,116 Class A shares proposed sale - Stock Titan
Jason Kelly to sell 109,767 Class A shares (NYSE: DNA) under Form 144 - Stock Titan
US Market Recap: Can Ginkgo Bioworks Holdings Inc maintain sales growthAnalyst Upgrade & Weekly Breakout Stock Alerts - baoquankhu1.vn
ProQR (PRQR) Partners with Ginkgo Bioworks to Boost AI-Driven Dr - GuruFocus
ProQR forms advisory board, partnership with Ginkgo as part of AI strategy - MSN
ProQR Forms AI Advisory Board and Partners with Ginkgo Bioworks - Intellectia AI
[144] Ginkgo Bioworks Holdings, Inc. SEC Filing - Stock Titan
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event - GlobeNewswire Inc.
ProQR in pact with Ginkgo as part of AI strategy (PRQR:NASDAQ) - Seeking Alpha
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board - Yahoo Finance
Aug Shorts: Is Ginkgo Bioworks Holdings Inc attractive for institutional investors2026 Analyst Calls & Weekly Setup with High ROI Potential - baoquankhu1.vn
Ginkgo Bioworks Divests Biosecurity Segment to Tower Biosecurity in Strategic Shift – Financial Impact and Pro Forma Results - Minichart
Ginkgo Bioworks Divests Biosecurity Unit, Refocuses Core Operations - TipRanks
Ginkgo Bioworks (DNA) divests Biosecurity segment, retains 20% Tower stake - Stock Titan
Institution Moves: What are Ginkgo Bioworks Holdings Incs recent SEC filings showingQuarterly Investment Review & Growth-Oriented Investment Plans - baoquankhu1.vn
Weekly Recap: What are Ginkgo Bioworks Holdings Incs recent SEC filings showingWatch List & Risk Managed Trade Strategies - baoquankhu1.vn
Quarterly Risk: Is Ginkgo Bioworks Holdings Inc attractive for institutional investors2026 Trade Ideas & Community Verified Watchlist Alerts - baoquankhu1.vn
(DNA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
8-K: Current report - Moomoo
Aug Shorts: Why is Ginkgo Bioworks Holdings Inc stock going up2026 Trends & Weekly Top Performers Watchlists - baoquankhu1.vn
Market Leaders: What are Ginkgo Bioworks Holdings Incs recent SEC filings showingInsider Buying & Consistent Income Trade Ideas - baoquankhu1.vn
DNA Stock Price, Quote & Chart | GINKGO BIOWORKS HOLDINGS INC (NYSE:DNA) - ChartMill
Is Ginkgo Bioworks Holdings Inc stock a value trap2026 Spike Watch & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Investment Review: Is Ginkgo Bioworks Holdings Inc a strong candidate for buy and hold2026 Volume Leaders & Verified Swing Trading Watchlists - baoquankhu1.vn
Performance Recap: Is Ginkgo Bioworks Holdings Inc a cyclical or defensive stockPortfolio Return Summary & Entry and Exit Point Strategies - baoquankhu1.vn
Wall Street Zen Downgrades Ginkgo Bioworks (NYSE:DNA) to Sell - MarketBeat
Pullback Watch: Is Ginkgo Bioworks Holdings Inc a strong candidate for buy and holdGold Moves & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Finanzdaten der Ginkgo Bioworks Holdings Inc-Aktie (DNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.68%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):